CannabidivarinCAS# 24274-48-4 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 24274-48-4 | SDF | Download SDF |
| PubChem ID | 11601669 | Appearance | Oil |
| Formula | C19H26O2 | M.Wt | 286.41 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-propylbenzene-1,3-diol | ||
| SMILES | CCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O | ||
| Standard InChIKey | REOZWEGFPHTFEI-JKSUJKDBSA-N | ||
| Standard InChI | InChI=1S/C19H26O2/c1-5-6-14-10-17(20)19(18(21)11-14)16-9-13(4)7-8-15(16)12(2)3/h9-11,15-16,20-21H,2,5-8H2,1,3-4H3/t15-,16+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Cannabidivarin is an effective anticonvulsant in a broad range of seizure models. 2. Cannabidivarin is a potent inhibitor against gamma 2 subunit of GABAA receptors by forming a maximum of number of interactions with the docking score (-5.3), it may serve as a novel drug with definite control over childhood absence epilepsy. |
| Targets | GABA Receptor |
Cannabidivarin Dilution Calculator
Cannabidivarin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.4915 mL | 17.4575 mL | 34.915 mL | 69.83 mL | 87.2875 mL |
| 5 mM | 0.6983 mL | 3.4915 mL | 6.983 mL | 13.966 mL | 17.4575 mL |
| 10 mM | 0.3491 mL | 1.7457 mL | 3.4915 mL | 6.983 mL | 8.7287 mL |
| 50 mM | 0.0698 mL | 0.3491 mL | 0.6983 mL | 1.3966 mL | 1.7457 mL |
| 100 mM | 0.0349 mL | 0.1746 mL | 0.3491 mL | 0.6983 mL | 0.8729 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Furanodienone
Catalog No.:BCN3010
CAS No.:24268-41-5
- Shikokianin
Catalog No.:BCN3278
CAS No.:24267-69-4
- 7-Methoxy-8-Hydroxy-4-Phenylcoumarin
Catalog No.:BCC8292
CAS No.:24258-36-4
- H-Phe(4-I)-OH
Catalog No.:BCC3259
CAS No.:24250-85-9
- H-Phe(4-Br)-OH
Catalog No.:BCC3157
CAS No.:24250-84-8
- 2,5-Bis(4-aminophenyl)-1,3,4-oxadiazole
Catalog No.:BCC8501
CAS No.:2425-95-8
- Solifenacin succinate
Catalog No.:BCC4580
CAS No.:242478-38-2
- Thalictrimine
Catalog No.:BCN5097
CAS No.:24240-04-8
- 3-Methyl-9H-carbazol-2-ol
Catalog No.:BCN4666
CAS No.:24224-30-4
- Mianserin
Catalog No.:BCC4134
CAS No.:24219-97-4
- Tabimorelin hemifumarate
Catalog No.:BCC5897
CAS No.:242143-80-2
- Farrerol
Catalog No.:BCN2481
CAS No.:24211-30-1
- Acetylcephalotaxine
Catalog No.:BCN5098
CAS No.:24274-60-0
- Sodium ferulic
Catalog No.:BCN8542
CAS No.:24276-84-4
- Boc-Glu-OtBu
Catalog No.:BCC3388
CAS No.:24277-39-2
- Mycophenolic acid
Catalog No.:BCC4803
CAS No.:24280-93-1
- Hesperidin methylchalcone
Catalog No.:BCN8125
CAS No.:24292-52-2
- Scandine
Catalog No.:BCN5099
CAS No.:24314-59-8
- Cephalotaxine
Catalog No.:BCN2957
CAS No.:24316-19-6
- 9-Fluorenylmethanol
Catalog No.:BCC2801
CAS No.:24324-17-2
- Tricosanoic acid
Catalog No.:BCN5394
CAS No.:2433-96-7
- Nagilactone C
Catalog No.:BCN4040
CAS No.:24338-53-2
- 6-Amino-1-methyluracil
Catalog No.:BCC8757
CAS No.:2434-53-9
- Apamin
Catalog No.:BCC7141
CAS No.:24345-16-2
Cannabidivarin is anticonvulsant in mouse and rat.[Pubmed:22970845]
Br J Pharmacol. 2012 Dec;167(8):1629-42.
BACKGROUND AND PURPOSE: Phytocannabinoids in Cannabis sativa have diverse pharmacological targets extending beyond cannabinoid receptors and several exert notable anticonvulsant effects. For the first time, we investigated the anticonvulsant profile of the phytocannabinoid Cannabidivarin (CBDV) in vitro and in in vivo seizure models. EXPERIMENTAL APPROACH: The effect of CBDV (1-100 muM) on epileptiform local field potentials (LFPs) induced in rat hippocampal brain slices by 4-aminopyridine (4-AP) application or Mg(2+) -free conditions was assessed by in vitro multi-electrode array recordings. Additionally, the anticonvulsant profile of CBDV (50-200 mg.kg(-1) ) in vivo was investigated in four rodent seizure models: maximal electroshock (mES) and audiogenic seizures in mice, and pentylenetetrazole (PTZ) and pilocarpine-induced seizures in rats. The effects of CBDV in combination with commonly used antiepileptic drugs on rat seizures were investigated. Finally, the motor side effect profile of CBDV was investigated using static beam and grip strength assays. KEY RESULTS: CBDV significantly attenuated status epilepticus-like epileptiform LFPs induced by 4-AP and Mg(2+) -free conditions. CBDV had significant anticonvulsant effects on the mES (>/=100 mg.kg(-1) ), audiogenic (>/=50 mg.kg(-1) ) and PTZ-induced seizures (>/=100 mg.kg(-1) ). CBDV (200 mg.kg(-1) ) alone had no effect against pilocarpine-induced seizures, but significantly attenuated these seizures when administered with valproate or phenobarbital at this dose. CBDV had no effect on motor function. CONCLUSIONS AND IMPLICATIONS: These results indicate that CBDV is an effective anticonvulsant in a broad range of seizure models. Also it did not significantly affect normal motor function and, therefore, merits further investigation as a novel anti-epileptic in chronic epilepsy models. LINKED ARTICLES: This article is part of a themed section on Cannabinoids. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.167.issue-8.
